Partnered Articles


Writing and Publishing
  • BioSpace’s Insights team writes and publishes the article
  • Includes up to two subject matter expert interviews of your choosing with BioSpace’s Insights team
  • Strategic guidance to optimize your content and demonstrate your thought leadership and subject matter expertise
  • Metrics provided after publication
Marketing and Promotion
  • Social promotion to over 275k BioSpace social followers
  • Email promotion in our GenePool newsletter for a week
  • Featured on the BioSpace homepage for a week
  • Long-term content hosting and SEO benefits
  • Creative assets provided
  • Includes an Article Reprint so you can further leverage your BioSpace article
Expert branded storytelling
Our writers and editors have deep industry and journalism experience to help you craft an engaging story.
Optimized publishing platform
First-in-class site authority to ensure your content is best placed on search engines and AI referrals.
Established media outlet
For three decades BioSpace has been a trusted source for biopharma resources, with widespread industry reach.
BioSpace is the leading platform for life sciences news and careers.
Benefit from BioSpace’s search authority, established media presence and reader loyalty. Elevate your brand and make an impression on key biopharma decision-makers to increase market visibility and stand out from your competitors. BioSpace’s life sciences audience continues to grow, with hundreds of thousands of subscribers, social followers and millions of site visitors, so you can feel confident you’re reaching the right people.
1.25m
average monthly website visits
500k
engaged email subscribers
275k
social followers
10k
new registrations every month
SK pharmteco’s Tatiana Nanda, chief technical officer of SK pharmteco Viral Vector North America discusses what gene therapy sponsors must account for sooner rather than later when preparing for GMP manufacturing.
CDMO-sponsor relationships have shifted from transactional outsourcing to strategic collaboration built on shared risk, regulatory fluency and technical insight. As rising compliance pressure and geopolitical volatility reshape manufacturing, partners like Rose BioSolutions argue that true value now comes from challenging assumptions, anticipating hurdles and protecting programs before problems surface.
Stem cell therapies vary widely yet many physicians still treat them as interchangeable. A more credible model requires diagnostics, product characterization and conventional medical context to determine who and when should receive regenerative treatment.
With oral cyclic peptides offering small molecule convenience and antibody‑like selectivity, the modality is gaining momentum. But bioavailability below 1%, minimal PK data and fragile synthesis still slow progress. Viva Biotech’s experts outlined how hybrid synthesis, ADME/PK modeling and AI‑guided design are expanding what peptide therapeutics can reach.
Efficacy plateaus, muscle loss and weight rebound are testing the limits of GLP-1 success, pushing companies toward new mechanisms and multitarget designs to close the gap. But progress depends on understanding disease biology and selecting the right drug candidates to derisk clinical trials.
The shift from ex vivo to in vivo gene delivery is rewriting the rules of viral vector manufacturing, forcing developers to rethink scale, purity, cell lines and analytics as vectors themselves become the drug. AGC Biologics is betting on stable producer lines, next‑gen purification and deeper characterization to meet the far stricter demands of in vivo therapies.
Brands On BioSpace
Have more questions about partnered articles or other strategic content and advertising solutions? Get in touch with our team to discuss how BioSpace can help you meet your business goals.